Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Mato, AR; Shah, NN; Jurczak, W; Cheah, CY; Pagel, JM; Woyach, JA; Fakhri, B; Eyre, TA; Lamanna, N; Patel, MR; Alencar, A; Lech-Maranda, E; Wierda, WG; Coombs, CC; Gerson, JN; Ghia, P; Le Gouill, S; Lewis, DJ; Sundaram, S; Cohen, JB; Flinn, IW; Tam, CS; Barve, MA; Kuss, B; Taylor, J; Abdel-Wahab, O; Schuster, SJ; Palomba, ML; Lewis, KL; Roeker, LE; Davids, MS; Tan, XN; Fenske, TS; Wallin, J; Tsai, DE; Ku, NC; Zhu, E; Chen, J; Yin, M; Nair, B; Ebata, K; Marella, N; Brown, JR; Wang, M

Mato, AR (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.; Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.

LANCET, 2021; 397 (10277): 892

Abstract

Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents d......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索